Brind.
  1. CStone Pharmaceuticals is seeking consensus on a global Phase III protocol for Pralsetinib, while sales increased by 500% year-over-year.

CStone is advancing drug candidate CS2009 through trials while reporting a 500% year-over-year sales increase and seeking FDA consensus.

1 report, 1 independent Updated Aug 31
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

CStone is advancing drug candidate CS2009 through trials while reporting a 500% year-over-year sales increase and seeking FDA consensus.

Keep exploring

Part of

CStone Pharmaceuticals is seeking consensus on a global Phase III protocol for Pralsetinib, while sales increased by 500% year-over-year. All 1 developments

Coverage

Newest first; wire copies grouped